{
  "abstract": "BACKGROUND: HeartMate 3 (Abbott Laboratories), a fully magnetically levitated left ventricular assist device (LVAD), has shown improved hemocompatibility vs. previous devices, but nationwide real-world data in Japan remain limited. METHODS AND RESULTS: Using the Japanese nationwide registry for Mechanically Assisted Circulatory Support (J-MACS), we analyzed patients who underwent de novo implantation of HeartMate 3 or HeartMate II between 2013 and 2025. The primary outcome was a composite of all-cause death, stroke, and device dysfunction requiring exchange or explantation within 2 years. In all, 978 patients were included in the study (HeartMate 3, n=486; HeartMate II, n=492). The 2-year cumulative incidence of the primary outcome was significantly lower in the HeartMate 3 group than in the HeartMate II group (9% vs. 23%; P<0.001). HeartMate 3 was independently associated with a lower risk of the primary outcome (adjusted hazard ratio 0.35; 95% confidence interval 0.23-0.51; P<0.001), which remained consistent in competing-risk and several statistically matched analyses. The incidence of hemocompatibility-related adverse events, including major bleeding, stroke, and device dysfunction, was significantly lower in the HeartMate 3 group. In contrast, 2- and 5-year overall mortality did not differ significantly between groups (<10% for both devices). CONCLUSIONS: In this nationwide Japanese registry, HeartMate 3 reduced major LVAD-related complications without improving survival, supporting its clinical advantages in contemporary LVAD management.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 19,
  "authors": [
    {
      "name": "Teruhiko Imamura"
    },
    {
      "name": "Masahiko Ando"
    },
    {
      "name": "Koichiro Kinugawa"
    },
    {
      "name": "Takashi Nishimura"
    },
    {
      "name": "Koichi Toda"
    },
    {
      "name": "Yoshikatsu Saiki"
    },
    {
      "name": "Hiroshi Niinami"
    },
    {
      "name": "Shinichi Nunoda"
    },
    {
      "name": "Goro Matsumiya"
    },
    {
      "name": "Hirokuni Arai"
    },
    {
      "name": "Masanobu Yanase"
    },
    {
      "name": "Norihide Fukushima"
    },
    {
      "name": "Takeshi Nakatani"
    },
    {
      "name": "Akira Shiose"
    },
    {
      "name": "Ikuko Shibasaki"
    },
    {
      "name": "Yasushi Sakata"
    },
    {
      "name": "Masaru Hatano"
    },
    {
      "name": "Minoru Ono"
    },
    {
      "name": "J-MACS Investigators"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/9gf48q1afh8je.bib",
  "cited_by": 0,
  "doi": "10.1253/circj.cj-26-0640",
  "fulltext_url": "https://www.jstage.jst.go.jp/article/circj/advpub/0/advpub_CJ-26-0640/_article",
  "id": "9gf48q1afh8je",
  "issns": [
    "1347-4820",
    "1346-9843"
  ],
  "landing_url": "https://www.jstage.jst.go.jp/article/circj/advpub/0/advpub_CJ-26-0640/_article",
  "language": null,
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "jstage-journal",
      "medicine/cardiovascular"
    ],
    [
      "openalex",
      "2204|Mechanical Circulatory Support Devices"
    ]
  ],
  "openalex": "W7222174444",
  "pdf_url": "https://www.jstage.jst.go.jp/article/circj/advpub/0/advpub_CJ-26-0640/_pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-16",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/9gf48q1afh8je.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:24Z",
      "native_id": "10.1253/circj.cj-26-0640",
      "source": "jstage",
      "url": "https://www.jstage.jst.go.jp/article/circj/advpub/0/advpub_CJ-26-0640/_article"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "jstage-journal:medicine/cardiovascular",
      "subfield": "cardiovascular"
    }
  ],
  "title": "Reduced Adverse Events Without Survival Benefit With HeartMate 3 vs. HeartMate II in Japan",
  "title_text": "Reduced Adverse Events Without Survival Benefit With HeartMate 3 vs. HeartMate II in Japan",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:24Z",
  "url": "https://research.draconitic.com/paper/9gf48q1afh8je",
  "venue": "Circulation Journal",
  "versions": []
}